Novartis To Buy UK Oncology Biotech Biz For Up To $1.5B
Swiss pharmaceutical heavyweight Novartis said Monday that it will buy London-based biotechnology company Myricx Bio for up to $1.5 billion in a move to strengthen its oncology pipeline....To view the full article, register now.
Already a subscriber? Click here to view full article